MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025

Company Overview - MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, specializing in the development, production, and commercialization of innovative biologics that enhance existing standards of care while reducing healthcare costs [8][9]. Product Development - MediWound is advancing EscharEx, a bioactive, multimodal debridement therapy for chronic and hard-to-heal wounds, currently in late-stage clinical development. EscharEx has shown safety and efficacy in previous Phase II trials and is set to initiate a Phase III study for venous leg ulcers (VLUs) imminently [7][9]. - The upcoming Phase III VALUE study will focus on EscharEx's application in VLUs, addressing a substantial unmet need in the treatment landscape for VLUs and diabetic foot ulcers (DFUs) [2][7]. Clinical Expertise - The virtual Key Opinion Leader (KOL) event will feature distinguished clinical experts, including Dr. John C. Lantis II, Dr. Vickie R. Driver, and Dr. Robert J. Snyder, who will discuss compelling results from Phase II studies, the upcoming Phase III study, and EscharEx's competitive advantages [2][3][4][5]. Market Opportunity - EscharEx presents a unique opportunity for significant market growth, with distinct advantages over the current market leader in the $360+ million chronic wound care market [9]. The event will highlight EscharEx's unique commercial potential and its role in addressing the unmet needs in wound care [2][7].